Premium
Janus kinase inhibitors role in bone remodeling
Author(s) -
Maruotti Nicola,
Corrado Addolorata,
Rotondo Cinzia,
Cantatore Francesco Paolo
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29149
Subject(s) - bone remodeling , janus kinase , microbiology and biotechnology , proinflammatory cytokine , rankl , bone resorption , rank ligand , cytokine , biology , bone cell , kinase , receptor , osteoclast , cancer research , inflammation , immunology , endocrinology , biochemistry , activator (genetics)
Janus kinases (JAKs) play a pleiotropic role in several important physiological processes, such as cell maturation, cell proliferation, and cell death, via providing transmission signals from several molecules, such as cytokines, interferons, hormones, and growth factors, to the nucleus. Bone physiology and remodeling are markedly influenced by proinflammatory cytokines. Among them, interleukin‐1 (IL‐1) and IL‐6 are considered potent stimulator of bone resorption. Several cytokine receptors, such as IL‐6 receptors, are characterized by tyrosine kinases of the JAK family associated with their intracellular domains. There is an emerging interest in the effects of JAKs inhibition on the cells involved in bone remodeling. JAK inhibitors represent a new class of molecules involved in the therapy of numerous immune‐mediated inflammatory diseases. In this review, we want to focus on the role of JAKs inhibitors on bone remodeling and on RANKL‐RANK‐OPG signal and inflammatory cytokines which are involved in the regulation of bone cells, such as osteoblasts and osteoclasts.